证券代码：688553 证券简称：汇宇制药 公告编号：2025-068 四川汇宇制药股份有限公司 关于增加2025年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、公司已于 2025 年 1 月 21 日召开了第二届董事会独立董事专门会议第二 次会议审议通过了《关于预计公司 2025 年度日常性关联交易的议案》，同意将该 议案提交公司董事会审议。公司已于 2025 年 1 月 23 日召开了第二届董事会第十 三次会议、第二届监事会第十三次会议，审议通过了《关于预计公司 2025 年度 日常性关联交易的议案》，关联董事丁兆对该议案进行了回避表决。具体内容详 见公司在上海证券交易所网站（www.sse.com.cn）披露的《汇宇制药关于预计 2025 年度日常性关联交易的公告》（公告编号：2025-009），公司预计 2025 年度日常 关联交易额度为人民币 2,750 万元，具体情况如下： 单位：万元 | 关联交易类 | 关联人 | 预 2025 | 年 | 占同类 | 20 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-066 四川汇宇制药股份有限公司 2025年半年度募集资金存放与实际使用情况 截至2025年6月30日，募集资金使用和结余情况见下表所示： 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）董事会根据《上海证券交 易所科创板上市公司自律监管指引第1号——规范运作》等有关规定及相关格式 要求，编制了《2025年半年度募集资金存放与实际使用情况专项报告》。具体如 下： 一、 募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意四川汇宇制药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2596号）核准，并经上海证券交易所 同意，公司由主承销商中信建投证券股份有限公司采用余额包销方式，向社会公 众公开发行人民币普通股（A股）股票63,600,000股，发行价为每股人民币38.87 元，共计募集资金2,472,132,000.00元，扣除承销和保荐费用（不含增值税） ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-069 四川汇宇制药股份有限公司 关于公司董事辞职暨补选非独立董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 四川汇宇制药股份有限公司（以下简称"公司"）董事会近日收到吴颖女士提 交的书面辞职报告。吴颖女士因个人原因申请辞去公司非独立董事、董事会战略 委员会委员职务，吴颖女士辞职后将不再担任公司任何职务。根据公司董事会提 名，经董事会提名委员会资格审核通过了非独立董事候选人任职资格，董事会同 意提名张春平先生为公司第二届董事会非独立董事候选人，该议案尚需提交公司 股东大会审议。 一、董事离任情况 根据《公司法》《公司章程》及相关规定，吴颖女士辞职后不会导致公司董 事会成员低于法定最低人数，不会影响董事会依法规范运作，也不会影响公司正 常的经营发展，吴颖女士的辞职报告自送达公司董事会之日起生效。 截至本公告披露之日，吴颖女士未持有公司股份，不存在应当履行而未履行 的承诺事项。公司董事会对吴颖女士在任职期间为公司发展作出的贡献表示衷心 感谢 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-071 四川汇宇制药股份有限公司 一、 说明会类型 本次投资者说明会以线上文字互动形式召开，公司将针对 2025 年上半年的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一）线上交流时间：2025 年 9 月 8 日（星期一）下午 14:00-15:00 （二）召开方式：线上文字互动 （三） 互动平台：上证路演中心（http://roadshow.sseinfo.com/） 三、 参加人员 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 9 月 5 日(星期五)16:00 前通过四川汇宇制药股份有限公司（以 下简称"公司"）邮箱 ir@huiyupharma.com 将需要了解和关注的问题提前提 供给公司。公司将在说明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 8 月 ...

中国经济网北京8月27日讯 汇宇制药(688553.SH)今日收报24.89元，跌幅7.99%。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00万股，发行价格为38.87 元/股，保荐机构、主承销商为中信建投证券，保荐代表人为杨泉、田斌，联席主承销商为国都证券。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制 药最终募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募 集资金19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地(二期)项目、汇宇创新药物研究院建设项 目、补充流动资金。 汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。目前该股处于破发状态。 ...

汇宇制药发行费用合计1.11亿元，其中中信建投证券、国都证券获得承销费9887.48万元。 汇宇制药发行募集资金总额为24.72亿元，扣除发行费用后，募集资金净额为23.61亿元。汇宇制药最终 募集资金净额比原计划多4.53亿元。汇宇制药于2021年10月18日披露的招股书显示，公司拟募集资金 19.07亿元，分别用于汇宇欧盟标准注射剂产业化基地(二期)项目、汇宇创新药物研究院建设项目、补充 流动资金。 中国经济网北京8月27日讯汇宇制药(688553.SH)今日收报24.89元，跌幅7.99%。 2021年10月26日，汇宇制药在上交所科创板上市，公开发行股票6360.00万股，发行价格为38.87元/股， 保荐机构、主承销商为中信建投（601066）证券，保荐代表人为杨泉、田斌，联席主承销商为国都证 券。 上市当日，汇宇制药盘中最高报42.59元，创上市以来股价最高点。目前该股处于破发状态。 ...

Group 1 - A-share market sees a decline in several innovative drug concept stocks, with Yuekang Pharmaceutical dropping over 10% [1] - Guangshengtang falls by 8%, while Lifang Pharmaceutical and Haishike decrease by over 7% [1] - Saili Medical declines by over 6%, and Huiyu Pharmaceutical drops by over 5% [1] - Jingxin Pharmaceutical experiences a decline of over 4%, with Shutaishen, Haiteshengwu, and Xinlitai all falling by over 3% [1]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has seen a significant increase in stock price, rising by 6.23% to HKD 16.37, following the announcement of a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huiyu Pharmaceutical's subsidiary, Sichuan Huichenxing [1] Group 1 - The company plans to appoint Sichuan Huichenxing as the exclusive agent for TY-9591 in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this potential agency agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and the agreement is expected to leverage Sichuan Huiyu's extensive sales and agency network [1] Group 2 - Sichuan Huiyu is a mature pharmaceutical enterprise with a complete industrial chain and rich experience in drug agency and sales in China [1] - The arrangement is anticipated to enhance sales and revenue for TY-9591, accelerate market penetration, and reduce the costs associated with establishing new sales channels [1] - Collaborating with a well-known pharmaceutical company is expected to strengthen the company's brand image [1]

Policy Developments - The 15th China Medical Device Supervision Management International Conference was held in Suzhou, emphasizing the support for high-end medical device innovation, including areas like medical robots and AI medical devices. The National Medical Products Administration (NMPA) has approved 52 innovative products this year, totaling 367 approved innovative products to date [2]. Product Approvals - The first photon counting spectral CT in China, developed by United Imaging Healthcare, received its medical device registration certificate from the NMPA, marking a significant breakthrough in medical technology [4]. - A nucleic acid detection kit for 14 central nervous system infection pathogens developed by China National Biological Products Group was approved, aiding in the diagnosis of CNS infections [5]. Financial Reports - Sanyou Medical reported a 17.77% year-on-year increase in revenue to 250 million yuan, with a net profit of 36.6 million yuan, reflecting a staggering 2083.64% growth [7]. - Junshi Biosciences reported a revenue of 1.168 billion yuan, a 48.64% increase year-on-year, but incurred a net loss of 413 million yuan, an improvement from a loss of 645 million yuan in the previous year [8]. Capital Market Activities - Fosun Pharma announced a licensing agreement with Sitala for the global development and commercialization of FXS6837, excluding China, and will receive shares valued at 5 million USD from Sitala [10]. - AbbVie reached an agreement to acquire Gilgamesh Pharmaceuticals' investigational drug bretisilocin for treating moderate to severe major depressive disorder [11]. - Nanxin Pharmaceutical plans to acquire a target asset group from Future Pharma for up to 480 million yuan, which includes various injection products and related intellectual property [12]. Industry Developments - Eli Lilly reported positive results from the Phase 3 clinical trial of its GLP-1 receptor agonist orforglipron for treating obesity in patients with type 2 diabetes, achieving significant weight loss and improvements in cardiovascular risk factors [14]. - A Chinese research team successfully transplanted gene-edited pig lungs into a brain-dead human, a world-first achievement that could alleviate organ donor shortages [16]. Corporate Changes - Dongcheng Pharmaceutical announced the resignation of its Deputy General Manager Wu Xiaoming due to work adjustments, with no impact on the company's operations [19].

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) announced a potential exclusive agency agreement for its core product TY-9591 with Sichuan Huicheng Pharmaceutical Co., Ltd. (Sichuan Huicheng), which is a wholly-owned subsidiary of Sichuan Huicheng [1] Group 1 - Sichuan Huicheng's board approved the potential agency agreement for TY-9591, which will allow Sichuan Huicheng to act as the exclusive agent in mainland China, excluding Hong Kong, Macau, Taiwan, and other overseas regions [1] - The initial milestone payment for this agreement could reach up to RMB 150 million [1] - The company is entering the commercialization phase for TY-9591, and if the agency arrangement is finalized, it will leverage Sichuan Huicheng's extensive sales and distribution network [1] Group 2 - Sichuan Huicheng is a mature pharmaceutical enterprise with a complete industry chain and rich experience in drug agency and sales in China [1] - The company believes that this arrangement will enhance the sales and revenue of TY-9591, accelerate market penetration, reduce costs associated with establishing new sales channels, and strengthen its brand image through collaboration with a well-known pharmaceutical company [1]